You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 133 No. 11, November 1998 TABLE OF CONTENTS
  Archives
  •  Online Features
  Paper
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (4)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Surgery, Other
 •Alert me on articles by topic

Bioavailability of Oral Ciprofloxacin in Early Postsurgical Patients

David J. Hackam, MD; Nicolas Christou, MD; Yasmin Khaliq, PharmD; Dianne R. Duffy, RN; David Vaughan, PhD; John C. Marshall, MD; Ori D. Rotstein, MD

Arch Surg. 1998;133:1221-1225.

Objective  To evaluate the absorption of oral ciprofloxacin within 24 hours of laparotomy for major elective surgery or peritonitis.

Design  In this prospective trial, patients were given a 750-mg oral dose the morning after major elective surgery (n=15) or surgery for peritonitis (n=7). Healthy volunteers served as controls (n=9). Serial urine and blood samples were drawn during the subsequent 12 hours, and pharmacokinetic measures were determined by standard high-performance liquid chromatography assay procedures.

Setting  Multicenter, university-affiliated hospitals.

Main Outcome Measures  Drug absorption as determined by area under the concentration time curve, maximum concentration, and time to maximum concentration.

Results  Oral bioavailability was reduced in elective surgery and peritonitis patients compared with controls. Among the 15 elective surgery patients, 27% (4/15) showed no absorption. The remaining 73% (11/15) had an area under the curve comparable with that of controls (8.3±1.6 (mg/[L·h]). Among all patients, those who showed drug absorption vs those who showed no absorption did not differ with respect to malignant neoplasm, case type, age, or biochemistry. However, patients showing no absorption were significantly heavier than patients showing absorption (patients showing absorption, 15%±3% over ideal body weight vs patients showing no absorption, 29%±6% over ideal body weight; P<.05). When elective surgery patients were stratified by presence or absence of obesity (25% above ideal body weight), mean area under the curve in nonobese patients was 9.80±2.37 vs 0.91±0.56 (mg/(L·h) in obese patients (P<.05).

Conclusions  Oral bioavailability was reduced for peritonitis surgery patients on the first day postoperatively, and for obese elective surgery patients. To achieve adequate serum levels requires continuation of intravenous antibiotics in patients with peritonitis, and adjustment of oral dosage in obese patients in the early period after elective surgery.


From the Department of Surgery, The Toronto Hospital and University of Toronto, Toronto, Ontario (Drs Hackam, Marshall, and Rotstein and Ms Duffy); Department of Surgery, McGill University, Montreal, Quebec (Dr Christou); Ottawa General Hospital, Ottawa, Ontario (Dr Khaliq); and Bayer Inc, Toronto (Dr Vaughan).



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Risks of interrupting drug treatment before surgery
Noble and Kehlet
BMJ 2000;321:719-720.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1998 American Medical Association. All Rights Reserved.